RT杂志文章SR Electronic T1 Multi-omics将IL-6转化信号与中性粒细胞细胞外陷阱形成联系起来嗜血杆菌COPD JF欧洲呼吸期刊Jo EUR RESPIR J FD欧洲呼吸学会SP 2003312 DO 10.1183 / 13993003188bet官网地址.03312-2020 A1 Winslow，索非亚A1 ODQVist，LINA A1 Diver，Sarah A1 RIISE，Rebecca A1 Abdillahi，Suado A1 Wingren，Cecilia A1 Lindmari，Cecilia A1 Lindmari，Helena A1 Wellner，Annika A1 Lundin，Sofia A1 Yrlid，Linda A1 AX，伊丽莎白A1 Djukanovic，Ratko A1 Sridhar，Sriram A1 Higham，Andrew A1 Singh，Dave A1 Southworth，Thomas A1 Brightling，Christopher E. A1 Olsson，Henric K. A1JEVNIKAR，ZALA YR 2021 UL //www.qdcxjkg.com/content/early/2021/03/10/13993003.03312-2020.Abstract AB背景IL-6转运信号（IL-6TS）作为一种致病机制突出然而，在慢性呼吸系统疾病中，IL-6TS在呼吸道中的司机和IL-6Ts途径激活患者的表型特征仍然很差。目的我们的目的是识别和表征COPD患者的气道IL-6.和患者阐明生物司机IL-6TS途径激活。我们使用IL-6TS特异性痰生物标志物轮廓（SIL-6R，IL-6，IL-1β，IL-8，MIP-1β），以将来自COPD患者的痰数据分层（n= 74;beat-copd）通过分层群集。IL-6TS签名与临床特征和痰微生物谱有关。在人中性粒细胞中研究了中性粒细胞细胞外阱形成（Netosis）和IL-6Ts的诱导。结果分层聚类显示了COPD患者的IL-6TS高级子集（n = 24），其与IL共享表型特征-6ts-high子集以前在哮喘中识别。该子集的特征在于痰细胞计数增加（p = 0.0001），持续的痰性嗜菌菌（P = 0.0004），降低了寿命质量（CRQ总分; P = 0.008），并且痰液中的促炎介质和MMP水平增加。 IL-6TS-high COPD patients showed an increase in Proteobacteria, with Haemophilus as the dominating genus. NETosis induced by H. influenzae was identified as a potential mechanism for increased soluble IL-6 receptor (sIL-6R) levels. This was supported by a significant positive correlation between sIL-6R and NETosis markers in bronchoalveolar lavage fluid from COPD patients.Conclusion IL-6TS pathway activation due to chronic colonization with Haemophilus may be an important disease driver in a subset of COPD patients.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Winslow reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Odqvist reports personal fees Astrazeneca, outside the submitted work.Conflict of interest: Dr. Diver has nothing to disclose.Conflict of interest: Dr. Riise reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Abdillahi reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Wingren reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Lindmark reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Wellner reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Lundin reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Yrlid reports other from AstraZeneca, outside the submitted work.Conflict of interest: Ms. Ax is an employee of, and hold stock/stock options, in AstraZeneca, which supported the study.Conflict of interest: Dr. Djukanovic reports personal fees from TEVA, personal fees from TEVA, personal fees from Novartis, personal fees from Novartis, personal fees from Synairgen, personal fees from GlaxoSmithKline, outside the submitted work.Conflict of interest: Dr. Sridhar reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Higham has nothing to disclose.Conflict of interest: Dr. Singh reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, personal fees from GlaxoSmithKline, personal fees from Glenmark, personal fees from Gossamerbio, personal fees from Menarini, personal fees from Mundipharma, personal fees from Novartis, personal fees from Peptinnovate, personal fees from Pfizer, personal fees from Pulmatrix, personal fees from Theravance, personal fees from Verona, outside the submitted work.Conflict of interest: Dr. Southworth has nothing to disclose.Conflict of interest: Dr. Brightling reports personal fees from GSK, personal fees from AzstraZeneca/MedImmune, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Roche, personal fees from Chiesi, outside the submitted work.Conflict of interest: Dr. Olsson reports other from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Jevnikar Rojnik reports and employee of, and hold stock/stock options, in AstraZeneca, which supported the study.